PMID- 23231769
OWN - NLM
STAT- MEDLINE
DCOM- 20130628
LR  - 20220113
IS  - 1756-9966 (Electronic)
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 31
IP  - 1
DP  - 2012 Dec 12
TI  - Alpha B-crystallin is a new prognostic marker for laryngeal squamous cell 
      carcinoma.
PG  - 101
LID - 10.1186/1756-9966-31-101 [doi]
AB  - BACKGROUND: Alpha B-crystallin (alphaB-crystallin) has been suggested to play an 
      important role in the development of solid tumors. However, the association 
      between alphaB-crystallin expression and clinicopathological characteristics of human 
      laryngeal carcinoma is not well defined. This study aimed to examine the 
      expression of alphaB-crystallin in human laryngeal squamous cell carcinoma (LSCC) and 
      investigate the relationship between its expression and the prognosis of LSCC. 
      METHODS: Real-time polymerase chain reaction (six LSCC samples, six 
      tumor-adjacent normal samples) and immunohistochemistry by tissue microarrays 
      (109 LSCC samples and 28 tumor-adjacent normal samples) were performed to 
      characterize expression of the alphaB-crystallin gene in LSCC. Kaplan-Meier survival 
      and Cox regression analyses were carried out to evaluate the prognosis of LSCC. 
      RESULTS: Real-time polymerase chain reaction and immunohistochemistry analysis 
      showed that the expression of alphaB-crystallin in LSCC was significantly higher than 
      that in tumor-adjacent normal tissues. Moreover, the expression level of 
      alphaB-crystallin protein in LSCC was significantly related to alcohol consumption (P 
      = 0.022), tumor differentiation (P = 0.007), pTNM stage (P = 0.041) and 5 years' 
      survival (P =0.030). COX multi-factor analysis showed that alphaB-crystallin (P = 
      .013), as well as pTNM stage (P =0.027) and lymphatic metastasis (P = 0.015) were 
      independent prognosis factors for LSCC. CONCLUSIONS: The data suggest that 
      alphaB-crystallin expression is correlated with malignant phenotypes of LSCC and it 
      may serve as a novel prognostic factor for LSCC.
FAU - Mao, Yuan
AU  - Mao Y
AD  - Department of Otolaryngology-Head and Neck Surgery, Jiangsu Province Official 
      Hospital, No.65 Jiangsu Road, Nanjing 210029, China.
FAU - Zhang, Da-Wei
AU  - Zhang DW
FAU - Lin, Hong
AU  - Lin H
FAU - Xiong, Lin
AU  - Xiong L
FAU - Liu, Ying
AU  - Liu Y
FAU - Li, Qing-Dong
AU  - Li QD
FAU - Ma, Jun
AU  - Ma J
FAU - Cao, Qing
AU  - Cao Q
FAU - Chen, Ren-Jie
AU  - Chen RJ
FAU - Zhu, Jin
AU  - Zhu J
FAU - Feng, Zhen-Qing
AU  - Feng ZQ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121212
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - 0 (alpha-Crystallin B Chain)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - Carcinoma, Squamous Cell/*genetics/metabolism/mortality/pathology
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/metabolism/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - RNA, Messenger/genetics/metabolism
MH  - alpha-Crystallin B Chain/*genetics/metabolism
PMC - PMC3551651
EDAT- 2012/12/13 06:00
MHDA- 2013/07/03 06:00
PMCR- 2012/12/12
CRDT- 2012/12/13 06:00
PHST- 2012/10/18 00:00 [received]
PHST- 2012/12/06 00:00 [accepted]
PHST- 2012/12/13 06:00 [entrez]
PHST- 2012/12/13 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
PHST- 2012/12/12 00:00 [pmc-release]
AID - 1756-9966-31-101 [pii]
AID - 10.1186/1756-9966-31-101 [doi]
PST - epublish
SO  - J Exp Clin Cancer Res. 2012 Dec 12;31(1):101. doi: 10.1186/1756-9966-31-101.